Based upon encouraging reports describing improvement of ALPS5 enteropathy with CTLA4-Ig treatment (12, 13) and since other therapies had been ineffective, we began subject 1 on a trial of CTLA4-Ig. Here, CTLA4 is linked to autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency.